Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization

Pharmaceutical Research

Volumn 25, Issue 6, 2008, Pages 1318-1326

  Maillet, Agnès ^a   Congy Jolivet, Nicolas ^a,b   Le Guellec, Sandrine ^c   Vecellio, Laurent ^a   Hamard, Sophie ^a   Courty, Yves ^a   Courtois, Anthony ^d,e   Gauthier, Francis ^a   Diot, Patrice ^a,b   Thibault, Gilles ^a,b   Lemarié, Etienne ^a,b   Heuzé Vourc'h, Nathalie ^a,f  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c DTF Medical   (France)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e IFREMER   (France)

^f INSERM   (France)

Author keywords

Aerosol; Aggregation; Anticancer antibody; Cetuximab; Lung cancer; Nebulizer

Indexed keywords

ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G; PHOSPHOPROTEIN PHOSPHATASE; RITUXIMAB;

AEROSOL; ARTICLE; CANCER THERAPY; CELL GROWTH; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DYNAMICS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL PROCEDURES; LUNG CANCER; MICROSCOPY; NEBULIZATION; PARTICLE SIZE; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL;

AEROSOLS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; NEBULIZERS AND VAPORIZERS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 43049090854     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9481-3     Document Type: Article

References (38)

1. 1. L. G. Collins C. Haines R. Perkel R. E. Enck 2007 Lung cancer: diagnosis and management Am. Fam. Phys. 75 56 63 L. G. Collins, C. Haines, R. Perkel, and R. E. Enck. Lung cancer: diagnosis and management. Am. Fam. Phys. 75:56–63 (2007).
2. 2. G. Scheuch M. J. Kohlhaeufl P. Brand R. Siekmeier 2006 Clinical perspectives on pulmonary systemic and macromolecular delivery Adv. Drug Deliv. Rev. 58 996 1008 16996638 10.1016/j.addr.2006.07.009 1:CAS:528:DC%2BD28Xht1Sht7jK G. Scheuch, M. J. Kohlhaeufl, P. Brand, and R. Siekmeier. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 58:996–1008 (2006).
3. 3. J. S. Patton P. R. Byron 2007 Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 67 74 17195033 10.1038/nrd2153 1:CAS:528:DC%2BD28XhtlGktbbL J. S. Patton, and P. R. Byron. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6:67–74 (2007).
4. 4. A. J. Bitonti J. A. Dumont 2006 Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway Adv. Drug Deliv. Rev. 58 1106 1118 16997417 10.1016/j.addr.2006.07.015 1:CAS:528:DC%2BD28Xht1Sht7jP A. J. Bitonti, and J. A. Dumont. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 58:1106–1118 (2006).
5. 5. J. S. Patton C. S. Fishburn J. G. Weers 2004 The lungs as a portal of entry for systemic drug delivery Proc. Am. Thorac. Soc. 1 338 344 16113455 10.1513/pats.200409-049TA 1:CAS:528:DC%2BD28XhsFGjsLs%3D J. S. Patton, C. S. Fishburn, and J. G. Weers. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1:338–344 (2004).
6. 6. R. U. Agu M. I. Ugwoke M. Armand R. Kinget N. Verbeke 2001 The lung as a route for systemic delivery of therapeutic proteins and peptides Respir. Res. 2 198 209 11686885 10.1186/rr58 1:CAS:528:DC%2BD3MXosVWmsro%3D R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2:198–209 (2001).
7. 7. L. Fabbri 2006 Pulmonary safety of inhaled insulins: a review of the current data Curr. Med. Res. Opin. 22 Suppl 3 21 28 10.1185/030079906X132712 L. Fabbri. Pulmonary safety of inhaled insulins: a review of the current data. Curr. Med. Res. Opin. 22 (Suppl 3):21–28 (2006).
8. 8. F. Gagnadoux A. Pape Le E. Lemarie S. Lerondel I. Valo V. Leblond J. Racineux T. Urban 2005 Aerosol delivery of chemotherapy in an orthotopic model of lung cancer Eur. Respir. J. 26 657 661 16204597 10.1183/09031936.05.00017305 1:CAS:528:DC%2BD2MXhtFyiu7jO F. Gagnadoux, A. Le Pape, E. Lemarie, S. Lerondel, I. Valo, V. Leblond, J. Racineux, and T. Urban. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur. Respir. J. 26:657–661 (2005).
9. 9. A. E. Hershey I. D. Kurzman L. J. Forrest C. A. Bohling M. Stonerook M. E. Placke A. R. Imondi D. M. Vail 1999 Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model Clin. Cancer Res. 5: 2653 2659 A. E. Hershey, I. D. Kurzman, L. J. Forrest, C. A. Bohling, M. Stonerook, M. E. Placke, A. R. Imondi, and D. M. Vail. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res. 5:2653–2659 (1999).
10. 10. N. V. Koshkina J. C. Waldrep L. E. Roberts E. Golunski S. Melton V. Knight 2001 Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model Clin. Cancer Res. 7 3258 3262 11595722 1:CAS:528:DC%2BD3MXnvF2rs7s%3D N. V. Koshkina, J. C. Waldrep, L. E. Roberts, E. Golunski, S. Melton, and V. Knight. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin. Cancer Res. 7:3258–3262 (2001).
11. 11. N. V. Koshkina E. S. Kleinerman 2005 Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases Int. J. Cancer 116 458 463 15800950 10.1002/ijc.21011 1:CAS:528:DC%2BD2MXmtl2kurc%3D N. V. Koshkina, and E. S. Kleinerman. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer 116:458–463 (2005).
12. 12. V. Knight N. V. Koshkina J. C. Waldrep B. C. Giovanella B. E. Gilbert 1999 Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice Cancer Chemother. Pharmacol. 44 177 186 10453718 10.1007/s002800050965 1:CAS:528:DyaK1MXkvVyhsL4%3D V. Knight, N. V. Koshkina, J. C. Waldrep, B. C. Giovanella, and B. E. Gilbert. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol. 44:177–186 (1999).
13. 13. P. M. Anderson S. N. Markovic J. A. Sloan M. L. Clawson M. Wylam C. A. Arndt W. A. Smithson P. Burch M. Gornet E. Rahman 1999 Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases Clin. Cancer Res. 5 2316 2323 10499599 1:CAS:528:DyaK1MXmsFyjsrg%3D P. M. Anderson, S. N. Markovic, J. A. Sloan, M. L. Clawson, M. Wylam, C. A. Arndt, W. A. Smithson, P. Burch, M. Gornet, and E. Rahman. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. 5:2316–2323 (1999).
14. 14. C. F. Verschraegen B. E. Gilbert E. Loyer A. Huaringa G. Walsh R. A. Newman V. Knight 2004 Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies Clin. Cancer Res. 10 2319 2326 15073107 10.1158/1078-0432.CCR-0929-3 1:CAS:528:DC%2BD2cXivFSqsrc%3D C. F. Verschraegen, B. E. Gilbert, E. Loyer, A. Huaringa, G. Walsh, R. A. Newman, and V. Knight. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res. 10:2319–2326 (2004).
15. 15. G. A. Otterson M. A. Villalona-Calero S. Sharma M. G. Kris A. Imondi M. Gerber D. A. White M. J. Ratain J. H. Schiller A. Sandler M. Kraut S. Mani J. R. Murren 2007 Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs Clin. Cancer Res. 13 1246 1252 17317836 10.1158/1078-0432.CCR-06-1096 1:CAS:528:DC%2BD2sXhvF2htr4%3D G. A. Otterson, M. A. Villalona-Calero, S. Sharma, M. G. Kris, A. Imondi, M. Gerber, D. A. White, M. J. Ratain, J. H. Schiller, A. Sandler, M. Kraut, S. Mani, and J. R. Murren. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin. Cancer Res. 13:1246–1252 (2007).
16. 16. B. P. H. Wittgen P. W. A. Kunst K. Born van der A. W. Wijk van W. Perkins F. G. Pilkiewicz R. Perez-Soler S. Nicholson G. J. Peters P. E. Postmus 2007 Phase I study of aerosolized slit cisplatin in the treatment of patients with carcinoma of the lung Clin. Cancer Res. 13 2414 2421 17438100 10.1158/1078-0432.CCR-06-1480 1:CAS:528:DC%2BD2sXkt1enu70%3D B. P. H. Wittgen, P. W. A. Kunst, K. van der Born, A. W. van Wijk, W. Perkins, F. G. Pilkiewicz, R. Perez-Soler, S. Nicholson, G. J. Peters, and P. E. Postmus. Phase I study of aerosolized slit cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res. 13:2414–2421 (2007).
17. 17. M. Z. Lin M. A. Teitell G. J. Schiller 2005 The evolution of antibodies into versatile tumor-targeting agents Clin. Cancer Res. 11 129 138 15671537 1:CAS:528:DC%2BD2MXhtVegsr8%3D M. Z. Lin, M. A. Teitell, and G. J. Schiller. The evolution of antibodies into versatile tumor-targeting agents. Clin. Cancer Res. 11:129–138 (2005).
18. 18. M. S. Nayeem R. H. Khan 2006 Recombinant antibodies in cancer therapy Curr. Protein Pept. Sci. 7 165 170 16611141 10.2174/138920306776359768 1:CAS:528:DC%2BD28XjsVCgtbc%3D M. S. Nayeem, and R. H. Khan. Recombinant antibodies in cancer therapy. Curr. Protein Pept. Sci. 7:165–170 (2006).
19. 19. L. Dellamary D. J. Smith A. Bloom S. Bot G. Guo H. Deshmuk M. Costello A. Bot 2004 Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics J. Control. Release 95 489 500 15023460 10.1016/j.jconrel.2003.12.013 1:CAS:528:DC%2BD2cXitVKgsbg%3D L. Dellamary, D. J. Smith, A. Bloom, S. Bot, G. Guo, H. Deshmuk, M. Costello, and A. Bot. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J. Control. Release 95:489–500 (2004).
20. 20. S. Schule W. Friess K. Bechtold-Peters P. Garidel 2007 Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations Eur. J. Pharm. Biopharm. 65 1 9 17034996 10.1016/j.ejpb.2006.08.014 S. Schule, W. Friess, K. Bechtold-Peters, and P. Garidel. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations. Eur. J. Pharm. Biopharm. 65:1–9 (2007).
21. 21. M. Maury K. Murphy S. Kumar A. Mauerer G. Lee 2005 Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G Eur. J. Pharm. Biopharm. 59 251 261 15661497 10.1016/j.ejpb.2004.07.010 1:CAS:528:DC%2BD2MXmtlCqtw%3D%3D M. Maury, K. Murphy, S. Kumar, A. Mauerer, and G. Lee. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur. J. Pharm. Biopharm. 59:251–261 (2005).
22. 22. A. J. Bitonti J. A. Dumont S. C. Low R. T. Peters K. E. Kropp V. J. Palombella J. M. Stattel Y. Lu C. A. Tan J. J. Song A. M. Garcia N. E. Simister G. M. Spiekermann W. I. Lencer R. S. Blumberg 2004 Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway Proc. Natl. Acad. Sci. U S A 101 9763 9768 15210944 10.1073/pnas.0403235101 1:CAS:528:DC%2BD2cXlvVaht7o%3D A. J. Bitonti, J. A. Dumont, S. C. Low, R. T. Peters, K. E. Kropp, V. J. Palombella, J. M. Stattel, Y. Lu, C. A. Tan, J. J. Song, A. M. Garcia, N. E. Simister, G. M. Spiekermann, W. I. Lencer, and R. S. Blumberg. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. U S A. 101:9763–9768 (2004).
23. 23. S. C. Low S. L. Nunes A. J. Bitonti J. A. Dumont 2005 Oral and pulmonary delivery of fsh-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis Hum. Reprod. 20 1805 1813 15817590 10.1093/humrep/deh896 1:CAS:528:DC%2BD2MXmvF2lu78%3D S. C. Low, S. L. Nunes, A. J. Bitonti, and J. A. Dumont. Oral and pulmonary delivery of fsh-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 20:1805–1813 (2005).
24. 24. N. Hanna R. Lilenbaum R. Ansari T. Lynch R. Govindan P. A. Janne P. Bonomi 2006 Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer J. Clin. Oncol. 24 5253 5258 17114658 10.1200/JCO.2006.08.2263 1:CAS:528:DC%2BD28XhtlemurbK N. Hanna, R. Lilenbaum, R. Ansari, T. Lynch, R. Govindan, P. A. Janne, and P. Bonomi. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol. 24:5253–5258 (2006).
25. 25. J. V. Heymach M. Nilsson G. Blumenschein V. Papadimitrakopoulou R. Herbst 2006 Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer Clin. Cancer Res. 12 4441s 4445s 16857825 10.1158/1078-0432.CCR-06-0286 1:CAS:528:DC%2BD28XntFSmtrc%3D J. V. Heymach, M. Nilsson, G. Blumenschein, V. Papadimitrakopoulou, and R. Herbst. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res. 12:4441s–4445s (2006).
26. 26. R. C. Lilenbaum 2006 The evolving role of cetuximab in non-small cell lung cancer Clin. Cancer Res. 12 4432s 4435s 16857823 10.1158/1078-0432.CCR-06-0097 1:CAS:528:DC%2BD28XntFSmtrg%3D R. C. Lilenbaum. The evolving role of cetuximab in non-small cell lung cancer. Clin. Cancer Res. 12:4432s–4435s (2006).
27. 27. D. D. Miller M. M. Amin L. B. Palmer A. R. Shah G. C. Smaldone 2003 Aerosol delivery and modern mechanical ventilation: in vitro / in vivo evaluation Am. J. Respir. Crit. Care Med. 168 1205 1209 12893644 10.1164/rccm.200210-1167OC D. D. Miller, M. M. Amin, L. B. Palmer, A. R. Shah, and G. C. Smaldone. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am. J. Respir. Crit. Care Med. 168:1205–1209 (2003).
28. 28. L. Vecellio None D. Grimbert M. H. Becquemin E. Boissinot A. Pape Le E. Lemarie P. Diot 2001 Validation of laser diffraction method as a substitute for cascade impaction in the European project for a nebulizer standard J. Aerosol Med. 14 107 114 11495481 10.1089/08942680152007954 1:STN:280:DC%2BD3MvkvVKnsA%3D%3D L. Vecellio None, D. Grimbert, M. H. Becquemin, E. Boissinot, A. Le Pape, E. Lemarie, and P. Diot. Validation of laser diffraction method as a substitute for cascade impaction in the European project for a nebulizer standard. J. Aerosol Med. 14:107–114 (2001).
29. 29. D. S. Salomon R. Brandt F. Ciardiello N. Normanno 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit. Rev. Oncol. Hematol. 19 183 232 7612182 10.1016/1040-8428(94)00144-I 1:STN:280:ByqA3snmtlc%3D D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:183–232 (1995).
30. 30. M. L. Janmaat F. A. E. Kruyt J. A. Rodriguez G. Giaccone 2003 Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or akt kinase pathways Clin. Cancer Res. 9 2316 2326 12796401 1:CAS:528:DC%2BD3sXksVajs78%3D M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or akt kinase pathways. Clin. Cancer Res. 9:2316–2326 (2003).
31. 31. G. N. Gill T. Kawamoto C. Cochet A. Le J. D. Sato H. Masui C. McLeod J. Mendelsohn 1984 Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity J. Biol. Chem. 259 7755 7760 6330079 1:CAS:528:DyaL2cXksFejsL8%3D G. N. Gill, T. Kawamoto, C. Cochet, A. Le, J. D. Sato, H. Masui, C. McLeod, and J. Mendelsohn. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259:7755–7760 (1984).
32. 32. W. K. Bleeker J. J. Lammerts van Bueren H. H. Ojik van A. F. Gerritsen M. Pluyter M. Houtkamp E. Halk J. Goldstein J. Schuurman M. A. Dijk van J. G. J. Winkel van de P. W. H. I. Parren 2004 Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy J. Immunol. 173 4699 4707 15383606 1:CAS:528:DC%2BD2cXnslWmtbs%3D W. K. Bleeker, J. J. Lammerts van Bueren, H. H. van Ojik, A. F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M. A. van Dijk, J. G. J. van de Winkel, and P. W. H. I. Parren. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173:4699–4707 (2004).
33. 33. J. Baselga 2001 The EGFR as a target for anticancer therapy-focus on cetuximab Eur. J. Cancer. 37 Suppl 4 16 22 10.1016/S0959-8049(01)00233-7 J. Baselga. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer. 37 (Suppl 4):16–22 (2001).
34. 34. R. U. Agu S. Valiveti K. S. Paudel M. Klausner P. J. Hayden A. L. Stinchcomb 2006 Permeation of win 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium vivo J. Pharm. Pharmacol. 58 1459 1465 17132208 10.1211/jpp.58.11.0006 1:CAS:528:DC%2BD2sXksVKmtr0%3D R. U. Agu, S. Valiveti, K. S. Paudel, M. Klausner, P. J. Hayden, and A. L. Stinchcomb. Permeation of win 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium vivo. J. Pharm. Pharmacol. 58:1459–1465 (2006).
35. 35. H. Steckel F. Eskandar 2003 Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers Eur. J. Pharm. Sci. 19 443 455 12907295 10.1016/S0928-0987(03)00148-9 1:CAS:528:DC%2BD3sXlvFyiu70%3D H. Steckel, and F. Eskandar. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur. J. Pharm. Sci. 19:443–455 (2003).
36. 36. I. Fangmark J. C. Carpin 1996 Protein nebulization J. Aerosol. Sci. 27 231 232 10.1016/0021-8502(96)00188-7 I. Fangmark, and J. C. Carpin. Protein nebulization. J. Aerosol. Sci. 27:231–232 (1996).
37. 37. H.C. Mahler R. Müller W. Frieß A. Delille S. Matheus 2005 Induction and analysis of aggregates in a liquid IgG1-antibody formulation Eur. J. Pharm. Biopharm. 59 3 407 417 15760721 10.1016/j.ejpb.2004.12.004 1:CAS:528:DC%2BD2MXit1Chsr8%3D H. C. Mahler, R. Müller, W. Frieß, A. Delille, and S. Matheus. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 59 (3):407–417 (2005).
38. 38. H. Schellekens 2005 Factors influencing the immunogenicity of therapeutic proteins Nephrol. Dial. Transplant. 6 3 9 H. Schellekens. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 6:3–9 (2005).